Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | KCNT1 | Q5JUK3 | 4/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | KCNMB1 | Q16558 | 1/20 | 0.38 |
| ▸ | KCNT2 | Q6UVM3 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13095475 | 0.85 | GABRA5 (0.40) | KCNT1GABRA5WDR5RIPK1KCNQ1 | |
| SCHEMBL13092739 | 0.84 | KCNT1 (0.41) | KCNT1GABRA5WDR5RIPK1KCNQ1 | |
| SCHEMBL21048472 | 0.83 | WDR5 (0.38) | KCNT1GABRA5WDR5RIPK1P2RX3 | |
| SCHEMBL3070727 | 0.83 | WDR5 (0.38) | KCNT1GABRA5WDR5RIPK1P2RX3 | |
| SCHEMBL13104922 | 0.82 | GABRA5 (0.39) | GABRA5WDR5RIPK1P2RX3P2RX2 | |
| SCHEMBL21091691 | 0.81 | AKR1C3 (0.44) | — | |
| SCHEMBL2260033 | 0.73 | P2RX3 (0.41) | KCNT1GABRA5RIPK1KCNQ1KCNH2 | |
| SCHEMBL3071028 | 0.73 | TTR (0.46) | — | |
| SCHEMBL2265558 | 0.71 | RIPK1 (0.41) | KCNT1RIPK1KCNQ1KCNH2CACNA1C | |
| SCHEMBL2265056 | 0.71 | RIPK1 (0.41) | KCNT1RIPK1KCNQ1KCNH2CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | claimed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | claimed |
| EP-2215049-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-2215049-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2019-06-12 | — | — | EP | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| WO-2009058298-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | NR1I2 598/4885CYP2C9 4126/4885KCNT1 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.